Lutikizumab (ABT-981) is an anti-IL-1α and IL-1β dual variable domain immunoglobulin. Lutikizumab binds and inhibits IL-1α and IL-1β. Lutikizumab can be used for the research of osteoarthritis.
ABT-981 shows simultaneously binding efficacy human IL-α and IL-1β molecules[1].
ABT-981 shows highly specific binding effects to IL-α and IL-1β over other IL-1 family members[1].
Lutikizumab (0.0001-1 mg/kg, i.p., once) shows effective inhibition to the IL-6 production induced by IL-1α and IL-1β[1].
References:
[1]. Lacy SE, et al. Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β. MAbs. 2015;7(3):605-19.